8 results about "Ivermectin" patented technology

The application provides a compound agent for preventing and treating termites based on Serratia marcescens, which comprises 7.75x10 8 ~2.63x10 12 CFU / mL of Serratia marcescens, and a pathogenic fungus or a biological pesticide or an insect growth regulator or a chemical agent; the pathogenic fungus is Beauvaria bassiana or Metarhizium anisopliae; the biological pesticide is ivermectin; the insect growth regulator is lufenuron or buprofezin or diflubenzuron; and the chemical agent is emamectin benzoate or indoxacarb. The compound agent has obvious synergistic effect on preventing and treating termites, reduces the use amount of single agent, is lower in cost, more efficient, stable and green.

The application relates to the technical field of fine chemical production, and particularly discloses a crystallization process of short-rod-shaped ivermectin, which comprises the following steps: dissolving ivermectin crude product in a crystallization solvent, heating to 50-55 DEG C, adding a crystallization agent, uniformly mixing, then cooling to 35-40 DEG C at a rate of 0.1-0.3 DEG C / min, adding ivermectin crystal seeds, continuously cooling to 5-15 DEG C, and incubating and crystallizing to obtain ivermectin products. The crystallization process of ivermectin provided by the application realizes effective control of the particle size and crystal habit of ivermectin products in the crystallization process by adopting a combination strategy of selecting a specific crystallization solvent, adding a crystallization agent and crystal seeds at specific stages, controlling the cooling rate and the incubation time, obtaining short-rod-shaped ivermectin products with uniform particle size distribution, and the products have good fluidity, are convenient for subsequent preparation application, do not need repeated crystallization for multiple times, effectively reduce the cost of the crystallization process, and have extremely high practical application value.

This invention relates to the field of veterinary drug technology, and proposes a compound composition for the prevention and treatment of shrimp hepatocellular carcinoma and its preparation method. The compound composition comprises the following raw materials: albendazole, ivermectin, and glycyrrhizic acid monoammonium salt. The components in the compound composition for the prevention and treatment of shrimp hepatocellular carcinoma provided by this invention work synergistically to safely control the disease and ensure the healthy and sustainable development of aquaculture.

Laboratory apparatus for evaluation and modulation of ivermectin drug–induced neurotoxicity using therapeutic intervention agents

The invention relates to an ivermectin and etoxazole compound suspending agent which comprises the following components in percentage by weight: 1-60% of effective components, 2-25% of synergistic additive composition, 0.1-10% of other additives and the balance of water. Wherein the effective components are ivermectin and etoxazole, the mass ratio of the ivermectin to the etoxazole is (1: 1)-(1: 30), the synergistic aid is a combination of iso-tridecanol polyoxyethylene ether and styrene-acrylate emulsion, and the mass ratio of the iso-tridecanol polyoxyethylene ether to the styrene-acrylate emulsion is (1: 10)-(10: 1). The two synergistic aids are combined for use, so that the pesticide effect performance of the ivermectin and etoxazole compound suspending agent can be improved, a synergistic interaction effect is achieved, and the prevention effect is superior to that of single use of the ivermectin and etoxazole compound suspending agent.

The invention discloses genetically engineered streptomyces as well as a construction method and application thereof. According to the present invention, with the application of the CRISPR-Cas9 gene editing technology, the aveA3 fragment in the Streptomyces avermitilis gene cluster capable of generating the ivermectin B1b compound is replaced with the milA3 fragment in the Streptomyces hygroscopicus gene cluster so as to obtain the gene engineering Streptomyces, such as Streptomyces avermitilis HU501-M, and the gene engineering Streptomyces HU501-M can be used to produce the ivermectin B1b compound, the constructed genetically engineered streptomyces can be used for preparing milbemycin D, and the compound has efficient insecticidal, acaricidal and antiparasitic activity, is high in safety to human beings and animals, and is environment-friendly. The main fermentation product of the genetically engineered streptomyces is milbemycins D, and the genetically engineered streptomyces has a good industrial development prospect.

The application belongs to the field of anti-parasitic drugs, especially a silica aerogel loaded ivermectin drug-loaded particle processing production line. The existing problems of the need to transport the prepared drug-loaded solid, complicated operation, the need for multiple power devices to stir, mix, high cost, incomplete discharge and complicated operation are solved. The scheme comprises a first mixing box and a collecting box, the outer wall of the first mixing box is fixedly connected with three support rods, the collecting box is located directly below the first mixing box, and the top of the first mixing box is fixedly communicated with a hollow circular table cylinder. In the application, the stirring assembly can fully stir the material, the first mixing box and the second mixing box utilize the power of one servo motor, the cost is greatly reduced, the first support block and the second support block can be lifted by the lifting assembly, the feeding and discharging process is completed, and the loading and unloading are not needed, so the work load is greatly reduced.

The application belongs to the technical field of antibiotic application, and discloses that microplastics affect the absorption of ciprofloxacin in the intestinal tract through the TLR4 / NF-kappa B pathway regulating P-gp protein. Our research finds that microplastics can activate the expression of P-gp glycoprotein in intestinal epithelial cells through the NF-kappa B pathway in the intestinal tract, thereby reducing the absorption of ciprofloxacin hydrochloride in the intestinal tract, and further affecting the core mechanism of pharmacokinetics and pharmacodynamics of ciprofloxacin hydrochloride in animals. Pyruvate ethyl effectively inhibits the NF-kappa B pathway. The application also finds that after ivermectin inhibits the P-gp glycoprotein of Caco2 cells, the P-gp glycoprotein cannot efflux ciprofloxacin hydrochloride, so that the content of ciprofloxacin hydrochloride in Caco2 cells increases. Therefore, the application also protects the application of ivermectin in preparing a promoter of the content of ciprofloxacin hydrochloride in Caco2 cells incubated with microplastics.